Type 2 diabetes mellitus and cardiovascular disease. Part I. Definition of the problem, stratification of cardiovascular risk and the main directions of prevention of cardiovascular diseases in patients with type 2 diabetes mellitus

Authors

  • S.M. Koval State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine
  • K.O. Yushko State Institution “L.T. Malaya National Therapy Institute of the National Academy of Medical Sciences of Ukraine”, Kharkiv, Ukraine

DOI:

https://doi.org/10.22141/2224-1485.13.5.2020.218437

Keywords:

type 2 diabetes mellitus, cardiovascular diseases, cardiovascular risk, glycemic control, arterial hypertension, dyslipidemia, antiplatelet therapy

Abstract

Currently, diabetes mellitus remains a global unsolved problem, and its prevalence continues to grow steadily, running rampant. This is especially true for type 2 diabetes mellitus, which belongs to the “diseases of civilization”, the development of which is more associated with lifestyle. Type 2 diabetes mellitus leads to the development of severe micro- and macrovascular complications, which are the main causes of disability and mortality in these patients. Moreover, type 2 diabetes mellitus is extremely often combined with already formed cardiovascular diseases, which significantly worsens the prognosis in patients. The article presents the main principles of modern recommendations for examination, stratification of cardiovascular risk, treatment and prevention of cardiovascular diseases in patients with type 2 diabetes mellitus based on the latest documents of European and American experts in the field of diabetology and cardiology.

Downloads

Download data is not yet available.

References

Diabetes in cardiovascular disease: to Braunwald’s heart sisease. Ed. by Darren K. McGuire, Nikolaus Marx. Elsevier, 2015. 398.

World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate and hyperglycaemia. Report of a WHO/IDF consultation. http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/ (June 14 2019).

Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association. Position Statement. Diabetes Care. 2014. 37(1). 81-90.

Definition, diagnosis and classification of diabetes mellitus and its complications: Report of WHO Consulation. Part 1: Diagnosis and classification of diabetes mellitus (WHO/NCD/NCS/99.2). intermediate and hyperglycaemia. World Health Organization, 1999.

Cosentino F., Grant P.J., Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020, Jan 7. 41(2). 255-323. doi: 10.1093/eurheartj/ehz486.

Довідник основних показників діяльності ендокринологічної служби України за 2016 рік. Ендокринолог. 2017. 22. № 1 (додаток 1). 40 с.

Маньковский Б.Н. Распространенность невыявленного сахарного диабета 2 типа и предиабета в Украине: результаты эпидемиологического исследования «ДИАПАЗОН». ДОМС, 2014. 5. 70-75.

Davies M.J., D’Alessio D.A., Fradkin J., Kernan W.N., Mathieu C., Mingrone G., Rossing P., Tsapas A., Wexler D.J., Buse J.B. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec. 41(12). 2669-2701. doi: 10.2337/dci18-0033.

Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2014. 1032 с.

Shahim B., De Bacquer D., De Backer G. et al. The prognostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in patients with coronary artery disease: a report from EUROASPIRE IV: a survey from the European Society of Cardiology. Diabetes Care. 2017. 40. 1233-1240.

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016. 37. 2129-2200. doi: 10.1093/eurheartj/ehw128.

Hinchliffe R.J., Brownrigg J.R., Andros G. et al. International Working Group on the Diabetic Foot. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab. Res. Rev. 2016. 32. 136-144.

Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2019. doi: 10.1093/eurheartj/ehz425.

International Diabetes Federation. IDF Diabetes Atlas. 8th ed. http://diabetesatlas.org/resources/2017-atlas.html (June 14 2019).

Коваль С.М., Снігурська І.О., Пенькова М.Ю., Мисниченко О.В., Літвінова О.М., Юшко К.О. Сучасні підходи до медикаментозного контролю артеріальної гіпертензії у хворих на цукровий діабет. Раціональна фармакотерапія. 2018. 2(47). 24-33.

Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016. 37. 2893-2962.

Piepoli M.F., Hoes A.W., Agewall S. et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2016. 37. 2315-2381.

Priori S.G., Blomstrom-Lundqvist C., Mazzanti A. et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 2015. 36. 2793-2867.

Valgimigli M., Bueno H., Byrne R.A. et al. ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2018. 39. 213-260.

Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 2018, Sep 1. 39(33). 3021-3104. doi: 10.1093/eurheartj/ehy339.

World Health Organization. Use of Ggycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. http://www.who.int/diabetes/publications/report-hba1c_2011.pdf (June 14 2019).

Koval S., Starchenko T., Iushko K. Clinical benefits of using dapagliflozin as part of the combination therapy in patients with arterial hypertension and type 2 diabetes. Journal of Hypertension. 2017. 35(e-Suppl. 2). 239.

Zelniker T.A., Wiviott S.D., Raz I. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019. 139. 2022-2031.

Zelniker T.A., Wiviott S.D., Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019. 393. 31-39.

Коваль С.М., Снігурська І.О., Пенькова М.Ю., Літвінова О.М., Божко В.В., Юшко К.О. Артеріальна гіпертензія та цукровий діабет: питання оптимізації контролю артеріального тиску. Артериальная гипертензия. 2018. 2(58). 9-18.

Коваль С.М., Старченко Т.Г., Юшко К.О., Мисниченко О.В. та ін. Динаміка ремоделювання лівого шлуночка у хворих на артеріальну гіпертензію в поєднанні з цукровим діабетом 2-го типу та ожирінням під впливом однорічної комбінованої терапії. Артериальная гипертензия. 2019. 3-4(65–66). 53-59.

Koval S.M., Yushko K.O., Snihurska I.O. et al. Relations of angiotensin- (1-7) with hemodynamic and cardiac structural and functional parameters in patients with hypertension and type 2 diabetes. Arterial Hypertens. 2019. Vol. 23. № 3. Р. 183-189. DOI: 10.5603/AH.a2019.0012.

Catapano A.L., Graham I., De Backer G. et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the ma-nagement of dyslipidaemias. Eur. Heart J. 2016. 37. 2999-3058.

Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association. Position Statement. Diabetes Care. 2014. 37(1). 81-90.

Published

2021-09-25

How to Cite

Koval, S., & Yushko, K. (2021). Type 2 diabetes mellitus and cardiovascular disease. Part I. Definition of the problem, stratification of cardiovascular risk and the main directions of prevention of cardiovascular diseases in patients with type 2 diabetes mellitus. HYPERTENSION, 13(5), 11–19. https://doi.org/10.22141/2224-1485.13.5.2020.218437

Issue

Section

To help clinicians

Most read articles by the same author(s)

1 2 3 > >>